Fixed dosing of her antibodies

Abstract

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

1 - 36 . (canceled) 
     
     
         37 . A method of treating cancer in a human patient comprising administering at least one fixed dose of pertuzumab to the patient, wherein the fixed dose is selected from the group consisting of approximately 420 mg, approximately 525 mg, approximately 840 mg, and approximately 1050 mg of pertuzumab. 
     
     
         38 . The method of  claim 37  wherein a fixed dose of pertuzumab is administered to the patient approximately every 3 weeks. 
     
     
         39 . The method of  claim 37  wherein the cancer is selected from the group consisting of ovarian cancer, peritoneal cancer, fallopian tube cancer, metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), prostate cancer, and colorectal cancer. 
     
     
         40 . The method of  claim 37  wherein the fixed dose is selected from the group consisting of 420 mg, 525 mg, 840 mg, and 1050 mg of pertuzumab. 
     
     
         41 . An article of manufacture comprising a vial containing a fixed dose of a HER antibody, wherein the fixed dose is selected from the group consisting of approximately 420 mg, approximately 525 mg, approximately 840 mg, and approximately 1050 mg of the HER antibody. 
     
     
         42 . The article of manufacture of  claim 41  wherein the HER antibody is pertuzumab. 
     
     
         43 . The article of manufacture of  claim 41  wherein the fixed dose is selected from the group consisting of 420 mg, 525 mg, 840 mg, and 1050 mg of the HER antibody. 
     
     
         44 . The article of manufacture of  claim 41  further comprising a package insert instructing the user to administer the fixed dose to a cancer patient. 
     
     
         45 . The article of manufacture of  claim 44  wherein the cancer is selected from the group consisting of ovarian cancer, peritoneal cancer, fallopian tube cancer, metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), prostate cancer, and colorectal cancer. 
     
     
         46 . The article of manufacture of  claim 44  wherein the package insert further instructs the user to administer the fixed dose to a cancer patient whose cancer displays HER expression, amplification, or activation. 
     
     
         47 . The article of manufacture of  claim 41  comprising two vials, wherein a first vial contains a fixed dose of approximately 840 mg of pertuzumab, and a second vial contains a fixed dose of approximately 420 mg of pertuzumab. 
     
     
         48 . The article of manufacture of  claim 41  comprising two vials, wherein a first vial contains a fixed dose of approximately 1050 mg of pertuzumab, and a second vial contains a fixed dose of approximately 525 mg of pertuzumab.